ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Dual-Targeting Peptide-Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion Nanoplatform.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 66 citations in OpenAlex.
- Luminescent Lanthanides in Biorelated Applications: From Molecules to Nanoparticles and Diagnostic Probes to Therapeutics.Chemical reviews · 2025Review
- Microenvironment-responsive peptide hydrogels: molecular mechanisms, design and frontiers.Frontiers in bioengineering and biotechnology · 2025Review
- Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Review
- Responsive Regulation of Energy Transfer in Lanthanide-Doped Nanomaterials Dispersed in Chiral Nematic Structure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- The role of Epstein-Barr virus in nasopharyngeal carcinoma.Frontiers in microbiology · 2023Review
- Molecular Characterisation of Epstein-Barr Virus in Classical Hodgkin Lymphoma.International journal of molecular sciences · 2022Article
- Lanthanide-Doped Upconversion Luminescent Nanoparticles-Evolving Role in Bioimaging, Biosensing, and Drug Delivery.Materials (Basel, Switzerland) · 2022Review
- Targeted delivery and stimulus-responsive release of anticancer drugs for efficient chemotherapy.Drug delivery · 2021Article
- The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.Molecules (Basel, Switzerland) · 2021Review
- Dual-Targeting Peptide-Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion Nanoplatform.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
Using Epstein-Barr virus (EBV)-induced cancer cells and HeLa cells as a comparative study model, a novel and safe dual-EBV-oncoproteins-targeting pH-responsive peptide engineering, coating, and guiding approach to achieve precision targeting and treatment strategy against EBV-associated cancers is introduced. Individual functional peptide sequences that specifically bind to two overexpressed EBV-specific oncoproteins, EBNA1 (a latent cellular protein) and LMP1 (a transmembrane protein), are engineered in three different ways and incorporated with a pH-sensitive tumor microenvironment (TME)-cleavable linker onto the upconversion nanoparticles (UCNP) NaGdF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.